<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="232928">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00043550</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH061410</org_study_id>
    <secondary_id>R01MH061410</secondary_id>
    <secondary_id>DSIR 83-ATAS</secondary_id>
    <nct_id>NCT00043550</nct_id>
  </id_info>
  <brief_title>Treatments for Depression: Drug Versus Psychotherapy</brief_title>
  <official_title>Efficacy of Dynamic Therapy Versus Selective Serotonin Reuptake Inhibitor for Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 4-8 month study, with a 2-year follow up period, will compare sertraline (Zoloft®),
      venlafaxine (Effexor®), supportive-expressive psychotherapy, and placebo to determine which
      is more effective in treating major depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MDD is one of the most prevalent psychiatric disorders. Different forms of psychotherapy for
      depression have been found effective. This study compares a form of dynamic psychotherapy
      called supportive-expressive psychotherapy to medication and to placebo.

      Participants are evaluated on 2 occasions, 1 week apart, before they are randomly assigned
      to receive either supportive-expressive psychotherapy, sertraline (Zoloft) (followed by
      venlafaxine [Effexor] if patients do not respond to sertraline), or placebo. The active
      phase of treatment lasts 4 months. The frequency of patients' visits depends on the assigned
      treatment.

      Patients who are randomized to receive medication or placebo are initially seen on a weekly
      basis, then less often, depending on the rate of symptomatic improvement. Patients who are
      randomized to psychotherapy are seen twice a week for the first 4 weeks, then once a week
      for the remaining 12 weeks. Outcome is monitored at week 2,4,6,7,8, 12, 15 and 16. At the
      end of the first 16 weeks of treatment, patients are thoroughly evaluated. Those who have
      responded to treatment are assigned to a continuation phase and are seen once a month for
      another 16 weeks. At the end of the 16-week continuation phase, patients are again evaluated
      and all treatments are stopped. Follow-up continues every 3 months for up to 2 years to
      ensure that the patients' depression remains under control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Ratings for Depression</measure>
    <time_frame>Measured at week, 2,4,6,7, 8,12,15 and 16 and then once a month</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>1 Sertraline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive sertraline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Venlafaxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive venlafaxine if they do not respond to sertraline by week 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Supportive-expressive psychotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive supportive-expressive psychotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Supportive Expressive Therapy</intervention_name>
    <description>The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.</description>
    <arm_group_label>3 Supportive-expressive psychotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Participants will receive sertraline.</description>
    <arm_group_label>1 Sertraline</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pill Placebo</intervention_name>
    <description>Participants will receive a pill placebo.</description>
    <arm_group_label>4 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Participants will receive venlafaxine.</description>
    <arm_group_label>2 Venlafaxine</arm_group_label>
    <other_name>Effexor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Major Depressive Disorder diagnosis

        Exclusion criteria:

          -  Psychotic or bipolar disorder diagnosis

          -  Substance dependence in the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Barber, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Barber JP, Muenz LR. The role of avoidance and obsessiveness in matching patients to cognitive and interpersonal psychotherapy: empirical findings from the treatment for depression collaborative research program. J Consult Clin Psychol. 1996 Oct;64(5):951-8.</citation>
    <PMID>8916624</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <lastchanged_date>June 12, 2012</lastchanged_date>
  <firstreceived_date>August 9, 2002</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Marna S. Barrett, PhD</investigator_full_name>
    <investigator_title>Research Projects Director</investigator_title>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
